| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
70,932,000 |
| Market
Cap: |
4.45(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$40.81 - $68.11 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on changing the paradigm for the treatment of rare genetic diseases of obesity, which are characterized by early-onset, severe obesity and hyperphagia, a pathological and insatiable hunger. Co. is developing IMCIVREE™ (setmelanotide) as a medicine strategy for a subset of individuals who have severe obesity due to genetic variants that impair the melanocortin-4 receptor pathway, a pathway in the brain that is responsible for regulating hunger, caloric intake and energy expenditure, which consequently affect body weight.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
193,837 |
311,071 |
592,569 |
983,254 |
| Total Sell Value |
$12,386,884 |
$18,701,767 |
$34,030,000 |
$49,639,906 |
| Total People Sold |
6 |
8 |
10 |
10 |
| Total Sell Transactions |
9 |
32 |
49 |
91 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jean Christophe |
Director |
– • – |
2025-06-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
7,000 |
|
- |
|
| Mathers Edward T |
|
– • – |
2025-06-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
7,000 |
|
- |
|
| Tetrault Lynn A. |
Director |
– • – |
2025-06-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
7,000 |
|
- |
|
| Bedrosian Camille L |
Director |
– • – |
2025-06-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
7,000 |
|
- |
|
| Mcgirr David W J |
Director |
– • – |
2025-06-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
7,000 |
|
- |
|
| Arbuckle Stuart A |
Director |
– • – |
2025-06-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
7,000 |
|
- |
|
| Good Jennifer L |
Director |
– • – |
2025-06-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
7,000 |
|
- |
|
| German Christopher Paul |
Corporate Controller & CAO |
• – – |
2025-06-10 |
4 |
AS |
$67.19 |
$139,016 |
D/D |
(2,069) |
1,889 |
|
-7% |
|
| German Christopher Paul |
Corporate Controller & CAO |
• – – |
2025-06-10 |
4 |
OE |
$17.97 |
$19,210 |
D/D |
1,069 |
3,958 |
|
- |
|
| Cramer Pamela J. |
Chief Human Resources Officer |
• – – |
2025-06-06 |
4 |
AS |
$68.05 |
$478,435 |
D/D |
(7,031) |
19,209 |
|
-8% |
|
| Cramer Pamela J. |
Chief Human Resources Officer |
• – – |
2025-06-06 |
4 |
OE |
$6.80 |
$47,811 |
D/D |
7,031 |
26,240 |
|
- |
|
| Mcgirr David W J |
Director |
– • – |
2025-06-03 |
4 |
AS |
$65.15 |
$4,267,494 |
D/D |
(65,431) |
3,000 |
|
-4% |
|
| Mcgirr David W J |
Director |
– • – |
2025-06-03 |
4 |
OE |
$4.59 |
$300,328 |
D/D |
65,431 |
68,431 |
|
- |
|
| Meeker David P |
President and CEO |
• • – |
2025-06-03 |
4 |
AS |
$65.04 |
$2,837,333 |
D/D |
(43,620) |
201,825 |
|
-4% |
|
| Meeker David P |
President and CEO |
• • – |
2025-06-03 |
4 |
OE |
$4.59 |
$200,216 |
D/D |
43,620 |
245,445 |
|
- |
|
| Smith Hunter C |
Chief Financial Officer |
• – – |
2025-05-30 |
4 |
AS |
$60.93 |
$1,437,010 |
D/D |
(23,400) |
109,929 |
|
2% |
|
| Smith Hunter C |
Chief Financial Officer |
• – – |
2025-05-30 |
4 |
OE |
$6.88 |
$160,992 |
D/D |
23,400 |
133,329 |
|
- |
|
| Mazabraud Yann |
EVP, Head of International |
• – – |
2025-04-29 |
4 |
AS |
$65.08 |
$438,946 |
D/D |
(6,745) |
37,655 |
|
-4% |
|
| Cramer Pamela J. |
Chief Human Resources Officer |
• – – |
2025-04-29 |
4 |
AS |
$65.09 |
$457,663 |
D/D |
(7,031) |
19,209 |
|
-4% |
|
| Cramer Pamela J. |
Chief Human Resources Officer |
• – – |
2025-04-29 |
4 |
OE |
$6.80 |
$47,811 |
D/D |
7,031 |
26,240 |
|
- |
|
| Mazabraud Yann |
EVP, Head of International |
• – – |
2025-04-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,405 |
44,400 |
|
- |
|
| Mazabraud Yann |
EVP, Head of International |
• – – |
2025-04-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,375 |
32,995 |
|
- |
|
| Mazabraud Yann |
EVP, Head of International |
• – – |
2025-04-08 |
4 |
AS |
$60.37 |
$1,082,497 |
D/D |
(17,750) |
22,620 |
|
9% |
|
| Cramer Pamela J. |
Chief Human Resources Officer |
• – – |
2025-04-08 |
4 |
AS |
$58.36 |
$1,248,490 |
D/D |
(20,760) |
19,209 |
|
9% |
|
| Cramer Pamela J. |
Chief Human Resources Officer |
• – – |
2025-04-08 |
4 |
OE |
$6.80 |
$278,853 |
D/D |
20,760 |
39,969 |
|
- |
|
357 Records found
|
|
Page 1 of 15 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
1.29 (2.09%) 
